ENGLEWOOD, Colo., Aug. 25, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that a previously approved 1-for-20 reverse split of its...
Aytu BioScience to Provide Fiscal Fourth Quarter and Year-End 2017 Business Update
Live Conference Call and Webcast Scheduled for August 31, 2017, at 10:30 a.m. ETENGLEWOOD, Colo., Aug. 24, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology,...
Aytu BioScience, Inc. Announces Closing of $11.8 Million Private Placement
ENGLEWOOD, Colo., Aug. 15, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the closing, on August 15, 2017, of its previously disclosed...
Aytu BioScience, Inc. Announces $11.5 Million Private Placement
ENGLEWOOD, Colo., Aug. 11, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has received subscriptions for a private placement in the...
Aytu BioScience Expands MiOXSYS® Distribution Network with a Fertility-Focused Company in Over 20 Countries in Europe
ENGLEWOOD, Colo., July 13, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the signing of an exclusive distribution agreement for...
Aytu BioScience Presents Clinical Findings for its MiOXSYS® System at 33rd Annual Meeting of the European Society of Human Reproduction and Embryology
ENGLEWOOD, Colo., July 5, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced seven presentations at the European Society of Human Reproduction...
Aytu BioScience Announces the Appointment of Gregory A. Gould as Permanent Chief Financial Officer
ENGLEWOOD, Colo., June 19, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the hiring of Gregory A. Gould as the company's full-time Chief...
Aytu BioScience Presents New Research Findings for its Natesto® Testosterone Nasal Gel at 112th American Urological Association Annual Meeting
ENGLEWOOD, Colo., May 17, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it presented one poster presentation illustrating safety...
Aytu BioScience Presents New Research Findings for its MiOXSYS® System at 112th American Urological Association Annual Meeting
ENGLEWOOD, Colo., May 15, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it presented two posters demonstrating new clinical findings...
Aytu BioScience Provides Third Quarter Fiscal 2017 Business Update
Live Conference Call and Webcast TODAY at 4:30 p.m. ETENGLEWOOD, Colo., May 11, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an overview of...
Aytu BioScience Announces the Acquisition of Nuelle, Inc., Developer and Marketer of Fiera® Female Personal Care Device
ENGLEWOOD, Colo., May 9, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the acquisition of Nuelle, Inc. ('Nuelle"), a women's sexual health...
Aytu BioScience to Provide Fiscal Third Quarter 2017 Business Update
Live Conference Call and Webcast Scheduled for May 11, 2017, at 4:30 p.m. ETENGLEWOOD, Colo., May 3, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today...
Aytu BioScience Presents Latest Clinical Findings for Natesto® at ENDO 2017, the National Endocrine Society’s Annual Scientific Meeting
ENGLEWOOD, Colo., April 4, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it presented two posters demonstrating the safety advantages...
Aytu BioScience Announces Divestiture of Primsol® to Allegis Holdings
Sale Price of $1.75 Million in Cash Further Supports Ongoing Commercialization of Natesto®ENGLEWOOD, Colo., April 3, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field...
Aytu BioScience Announces Peer-Reviewed Publication of Fourth Clinical Study Demonstrating the Utility of MiOXSYS® in the Assessment of Male Infertility
ENGLEWOOD, Colo., March 14, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the publication of a peer-reviewed journal article demonstrating...
Aytu BioScience Completes Successful Warrant Tender Offer and Receives $2.2 Million from Exercise of Warrants
ENGLEWOOD, Colo., March 1, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the successful completion of its tender offer to amend and...
Aytu BioScience Announces Expansion of U.S. Sales Team to Support Increasing Growth of Natesto Prescriptions and Revenues
Increasing Number of U.S. Territories by 20%ENGLEWOOD, Colo., Feb. 22, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the expansion of its...
Aytu BioScience Provides Second Quarter Fiscal 2017 Business Update and Financial Results
Product Revenues Increased 77% from Same Quarter in Prior Year; Cash Burn Reduced by 47% from Previous QuarterForecasting Cash Flow Breakeven in ~18 MonthsLive Conference Call and Webcast TODAY at 4:30 p.m. ETENGLEWOOD, Colo., Feb. 9, 2017 -- Aytu BioScience, Inc....
Aytu BioScience Announces Two Presentations at Endocrine Society 2017 Annual Meeting Highlighting Benefits of Natesto® (Testosterone) Nasal Gel in Men
ENGLEWOOD, Colo., Feb. 1, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that two posters demonstrating clinical data for Natesto®...
Aytu BioScience to Provide Fiscal Second Quarter 2017 Business Update
Live Conference Call and Webcast Scheduled for February 9, 2017, at 4:30 p.m. ETENGLEWOOD, Colo., Jan. 31, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology,...
Aytu BioScience to Present at Noble Capital Markets’ 13th Annual Investor Conference
Presentation on Tuesday, January 31st at 1:30 pm ETENGLEWOOD, Colo., Jan. 24, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that Josh...
Aytu BioScience Announces Two Presentations Highlighting Benefits of Natesto® (Testosterone) Nasal Gel in Men at American Urological Association Annual Meeting
ENGLEWOOD, Colo., Jan. 18, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that two posters demonstrating clinical data for Natesto®...
Aytu BioScience to Present at Biotech Showcase 2017 Investor Conference
Presentation on Monday, January 9th at 9:30 AM Pacific TimeENGLEWOOD, Colo., Jan. 4, 2017 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that...
Aytu BioScience Launches Asian Distribution Network for Company’s MiOXSYS® System for Male Infertility
Signs Distribution Agreements with Established Medical Distributors in Japan, Korea, Hong Kong, Macau, and IndiaENGLEWOOD, Colo., Dec. 15, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel...
Aytu Bioscience Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation ENGLEWOOD, Colo., Dec, 5, 2016 -- Aytu Bioscience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global...
Aytu BioScience to Present at 9th Annual LD Micro Investor Conference
Presentation on Thursday, December 8th at 9:30 AM PTENGLEWOOD, Colo., Dec. 1, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that Josh...
Aytu BioScience Announces Study Findings Demonstrating Clinical Improvements in Erectile Function and Mood in Hypogonadal Men Treated with Natesto® Nasal Testosterone Gel
Natesto Improves All Five Domains of Erectile FunctionENGLEWOOD, Colo., Nov. 30, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the summary...
Aytu BioScience to Webcast, Live, at VirtualInvestorConferences.com December 1
Company invites individual and institutional investors to attend interactive real-time virtual VirtualInvestorConferences.comENGLEWOOD, Colo., Nov. 28, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization...
Aytu BioScience Announces Publication of MiOXSYS® Data Demonstrating Clinical Utility in Diagnosing Male Infertility
Data Establishes a Clear Protocol for Reproducible Sampling and a Clinical Cut-Off Value for Distinguishing Infertile MenENGLEWOOD, Colo., Nov. 17, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of...
Aytu BioScience Provides First Fiscal Quarter 2017 Business Update
Live Conference Call and Webcast TODAY at 4:30 p.m. ETENGLEWOOD, Colo., Nov. 7, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, provided today an overview of...
Aytu BioScience to Provide Fiscal First Quarter 2017 Business Update
Live Conference Call and Webcast Scheduled for November 7, 2016, at 4:30 p.m. ETENGLEWOOD, Colo., Nov. 3, 2016 -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology,...
Aytu BioScience Announces Closing of Public Offering
ENGLEWOOD, Colo., Nov. 2, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced underwritten public...
Aytu BioScience Further Demonstrates Clinical Utility for MiOXSYS™ System as an Aid in the Diagnosis of Male Infertility
Presents Clinical Findings at 72nd Annual Meeting of the American Society of Reproductive MedicineENGLEWOOD, Colo., Nov. 1, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the...
Aytu BioScience to Present at Two Upcoming Investor Conferences
ENGLEWOOD, Colo., Sept. 14, 2016 -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it will present at two upcoming investor conferences in...
Aytu BioScience Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation ENGLEWOOD, Colo., Sept. 13, 2016 -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global...
Aytu BioScience to Webcast, Live, at VirtualInvestorConferences.com September 8
Company invites individual and institutional investors to attend interactive real-time virtual VirtualInvestorConferences.com ENGLEWOOD, Colo., Sept. 6, 2016 --Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization...
Aytu BioScience to Present at 2016 BioPharm America Conference
ENGLEWOOD, Colo., Sept. 6, 2016 -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that Chief Operating Officer Jarrett Disbrow will present at the...
Aytu BioScience Provides Fiscal Fourth Quarter and Fiscal Year 2016 Business Update
Live Conference Call and Webcast Today at 4:30 p.m. ETENGLEWOOD, Colo., Sept. 1, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, provided today a review of...
Aytu BioScience to Provide Fiscal Fourth Quarter and Fiscal 2016 Business Update
Live Conference Call and Webcast Scheduled for September 1, 2016, at 4:30 p.m. ETENGLEWOOD, Colo., Aug. 25, 2016 -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology,...
Aytu BioScience to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
ENGLEWOOD, Colo., Aug. 18, 2016 -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it will present at the Rodman & Renshaw 18th Annual Global...
Aytu BioScience, Inc. Announces Common Stock Purchase Agreement for up to $10.5 Million
Equity Commitment Supports the U.S. Launch of Natesto® and the Company's Commercial ExpansionENGLEWOOD, Colo., July 28, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU) ("Aytu"), a specialty pharmaceutical company focused on global commercialization of novel products...
Aytu BioScience Announces Publication of Peer-Reviewed Study Demonstrating the Utility of MiOXSYS™ in the Assessment of Male Infertility
ENGLEWOOD, Colo., July 21, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the publication of the first peer-reviewed journal article...
Aytu BioScience Strengthens Board with the Appointment of Two Pharmaceutical Industry Veterans as Independent Directors
ENGLEWOOD, Colo., July 13, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the addition of John Donofrio, Jr., a 24-year pharmaceutical...
Aytu BioScience Presents Clinical Findings for its MiOXSYS™ System at 32nd Annual Meeting of the European Society of Human Reproduction and Embryology
ENGLEWOOD, Colo., July 7, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it presented three posters demonstrating the potential of...
Aytu BioScience Provides Update on Natesto Product Launch
Live Conference Call and Webcast TODAY at 4:30 p.m. ETENGLEWOOD, Colo., July 6, 2016 -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, will provide an overview of...
Aytu BioScience to Host Conference Call to Detail Company’s Natesto® U.S. Launch Plans
Live Conference Call and Webcast Scheduled for July 6, 2016, at 4:30 p.m. ETENGLEWOOD, Colo., June 30, 2016 -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology,...
Aytu BioScience Announces Presentation of Clinical Data Highlighting Efficacy of Natesto™ (Testosterone) Nasal Gel in Men with Seasonal Allergies
Poster Presentation at 71st Annual Canadian Urological Society MeetingENGLEWOOD, Colo., June 28, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced...
Aytu BioScience to Execute Reverse Stock Split in Anticipation of Uplisting its Common Stock to a National Exchange
Company Announces 1:12 Reverse Stock SplitENGLEWOOD, Colo., June 22, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced today a one-for-twelve (1:12)...
Aytu BioScience Announces European Distribution Agreements for Company’s MiOXSYS™ System for Male Infertility
Establishes Initial European Distribution Network with Established Reproductive Health Companies for MiOXSYS™ SystemENGLEWOOD, Colo., June 13, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of...
Aytu BioScience Announces Study Initiation and First Patient Dosing in Prostate Cancer Clinical Study with Hybridyne Imaging Technologies for ProstaScint® in Combination with Hybridyne’s ProxiScan™ Transrectal Camera
ENGLEWOOD, Colo., June 6, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has begun enrollment and patient dosing in their prostate...
